China Academy of Chinese Medical Sciences - China
Author Profile
Orcid
Scopus
🎓 Early Academic Pursuits
Assoc. Prof. Dr. Chong Qiu began his academic journey at Peking University, where he completed his Bachelor's and Doctorate in Pharmaceutical Science in 2014 and 2019, respectively. His early academic exposure to cutting-edge pharmaceutical science provided a strong foundation for his future research endeavors in nanomedicine, targeted drug delivery, and traditional Chinese medicine.
💼 Professional Endeavors
Following his doctoral studies, Dr. Qiu joined the China Academy of Chinese Medical Sciences as an Associate Professor at the Artemisinin Research Center and the Institute of Chinese Materia Medica. His role encompasses leadership in groundbreaking research projects, specifically in nanocarriers for siRNA delivery, oral protein and peptide transport systems, and targeted nanoparticulate drug delivery systems. His commitment to advancing medical science is demonstrated through his active involvement as a Young Scientist Board Member for prestigious journals like Asian Journal of Pharmaceutical Sciences, iMeta, and Traditional Medicine Research and Exploration.
🔬 Contributions and Research Focus
Dr. Qiu's research primarily focuses on nanomedicine and its applications in drug delivery. His innovative work in developing nano-carriers for oral protein and peptide transport systems has pushed the boundaries of what is possible in targeted drug delivery. In particular, his contributions to enhancing the tumor penetration of drugs across the blood-brain barrier using endoplasmic reticulum membrane hybrid siRNA nanoplexes have gained significant recognition. Dr. Qiu's exploration of nanomedicine technologies and their application in both modern and traditional medical systems is not only innovative but transformative for future therapeutic strategies.
🌍 Impact and Influence
Over the past few years, Dr. Qiu's research has had a profound impact, particularly in the fields of nanomedicine, cancer immunotherapy, and the pharmacodynamics of traditional Chinese medicines. His work on utilizing nebulized milk exosomes loaded with siRNA to combat pulmonary fibrosis by inhibiting EMT pathways, as published in Journal of Nanobiotechnology, exemplifies his forward-thinking approach. The international research community has recognized his efforts, with his papers being widely cited in high-impact journals such as Nature Communications, iMeta, and Journal of Nanobiotechnology.
🏆Academic Cites
Dr. Qiu's publications have garnered citations in numerous top-tier journals, reflecting his significant contributions to the scientific community. His 2019 paper in Nature Communications, where he explored siRNA delivery through hybrid nanoplexes, has been particularly influential, given the journal’s impact factor of 16.6. His other works, such as the development of calcium phosphate nanocarriers for tumor-targeted therapy and advancements in siRNA delivery via nano-carrier architecture engineering, have solidified his reputation as a leading voice in nanomedicine.
🌟 Legacy and Future Contributions
Dr. Chong Qiu's legacy in the field of nanomedicine continues to grow, with several innovative contributions already shaping the future of targeted drug delivery systems and cancer treatment. His focus on overcoming the endosomal/lysosomal barriers in nanodrug delivery has been recognized as one of the leading strategies in modern pharmaceutical research. Moving forward, Dr. Qiu's pioneering work in nano-based therapeutic approaches promises to yield new insights and technologies that will revolutionize the treatment of complex diseases.
📝 Nanomedicine
The keyword nanomedicine forms the core of Dr. Qiu's research, encapsulating his commitment to harnessing nanoscale technologies for therapeutic innovations. His groundbreaking work in the area of siRNA delivery and nanoparticulate drug systems has highlighted the potential of nanomedicine in creating targeted, effective, and less invasive treatment options, especially in the fight against cancer and other critical diseases.
Notable Publication
📝Nebulized milk exosomes loaded with siTGF-β1 ameliorate pulmonary fibrosis by inhibiting EMT pathway and enhancing collagen permeability
Authors: Qiu, C., Zhao, Z., Xu, C., Wang, H., Shi, Y.
Journal: Journal of Nanobiotechnology
Year: 2024
Citations: 2
📝Recent trends in preparation and biomedical applications of iron oxide nanoparticles
Authors: Meng, Y.Q., Shi, Y.N., Zhu, Y.P., Qiu, C., Wang, J.G.
Journal: Journal of Nanobiotechnology
Year: 2024
Citations: 15
📝Photoaffinity probe-based antimalarial target identification of artemisinin in the intraerythrocytic developmental cycle of Plasmodium falciparum
Authors: Gao, P., Wang, J., Qiu, C., Dai, L., Wang, J.
Journal: iMeta
Year: 2024
Citations: 0
📝Glycyrrhetinic acid inhibits non-small cell lung cancer via promotion of Prdx6- and caspase-3-mediated mitochondrial apoptosis
Authors: Guo, Q., Zhao, M., Wang, Q., Qiu, C., Wang, J.
Journal: Biomedicine and Pharmacotherapy
Year: 2024
Citations: 1
📝Enhanced tumor penetration across the blood-brain barrier: endoplasmic reticulum membrane hybrid siRNA nanoplexes
Authors: Qiu, C., Liang, S.T., Tu, Q.C., Xia, F., Wang, J.G.
Journal: Materials Today Nano
Year: 2024
Citations: 1